vantuylen

Six Things Providers Should Know About HIV-Associated Neurocognitive Disorders

[From The Body Pro, January 23, 2019] “Early in the epidemic, one of the most terrifying consequences of late-stage, AIDS-related illness was the various neurocognitive disorders, the worst of which was dementia. At that time, with no effective antiretroviral therapies, the virus quickly penetrated the blood-brain barrier. AIDS dementia complex, along with early opportunistic infections […]

Six Things Providers Should Know About HIV-Associated Neurocognitive Disorders Read More »

The forgotten: Living with HIV in war-ravaged Yemen

[From Al Jazeera, January 21st 2019] “Sanaa, Yemen – With each breath he took, the red rashes on Ahmad’s cheeks appeared to get brighter and brighter. The eight-year-old had just made his way up the stairs of the al-Jumhurriya hospital in the Yemeni capital Sanaa, one of the few health centres in the war-ravaged country that

The forgotten: Living with HIV in war-ravaged Yemen Read More »

Efavirenz in pregnancy is at least as safe as other antiretrovirals

[From aidsmap, January 17th 2019] “An individual patient data analysis of almost 25,000 pregnancies in women living with HIV has found that the rate of birth defects following exposure to efavirenz was not statistically different, and may even be lower than in infants exposed to other antiretrovirals. The analysis by Professor Begoña Martinez de Tejada

Efavirenz in pregnancy is at least as safe as other antiretrovirals Read More »

African women prefer multipurpose HIV prevention products

[From Avert, January 16th 2019] “Young women in South Africa and Kenya would prefer injectable HIV prevention products that are multipurpose and can also prevent pregnancy over oral or ring-based pre-exposure prophylaxis (PrEP) products. The findings were revealed in a ‘discrete choice experiment’ (DCE) conducted among 536 women aged 18-30 in South Africa and Kenya

African women prefer multipurpose HIV prevention products Read More »

Scroll to Top